Interview with Erika Koppers, COO & GM, Roche SA
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Roche Diagnostics has a proud tradition of innovation in healthcare around the globe. We are committed to making a real difference in people’s lives by providing products and services for the diagnosis of diseases. One of our objectives is to develop new diagnostic tools to support healthcare professionals and patients, in their efforts to manage diseases and healthcare costs.
Our leadership in innovation is evident in our Early Infant Diagnosis of HIV program built on our globally renowned Polymerase Chain Reaction (PCR) technology. The introduction of a Dried Blood Spot (DBS) sampling option for this program has had a direct benefit for all stakeholders in the healthcare industry namely, patients, clinicians, administrators and program funders.
Roche Diagnostics’ adoption of innovation within these programs is not limited to the development of in-vitrodiagnostic assays for high burden diseases such as HIV/AIDS and TB, but also encompasses other aspects of process workflow in an effort to create sustainable solutions for the challenges posed within resource-limited regions. This is achieved through the AmpliCare Initiative, which was our proactive response to the need to expand diagnostics to these settings.
We are committed to capacity building initiatives through ongoing certified training of laboratory scientists at the Roche PCR Academy in Johannesburg, to ensure highest results, quality and reliability. This training includes education of Health Care Professionals on molecular theory and techniques enabling them to deliver better patient management outcomes.
Through Roche’s research and development initiatives, we also apply our expertise to develop novel solutions, precise and robust diagnostic tests, automated systems and integrated solutions in the fields of Clinical Chemistry, Hematology, Coagulation and Immunodiagnostics.
We believe that through continued effort and investment in the latest innovations in diagnostics, Roche can make a positive, sustainable and cost-effective contribution to developing world healthcare.
Roche Diagnostics is the world leader in in vitro diagnostics. Roche Diagnostics offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories in the fields of diabetes care and anticoagulation therapy, molecular biology, clinical chemistry, immunology and applied science.
Contact Details
Roche Products (Pty) Ltd
9 Will Scarlet Road
P O Box 1927,Randburg
2125, South Africa
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
See our Cookie Privacy Policy Here
